Class action lawsuit filed against Immutep for alleged securities fraud during 2025-2026 trial period

Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Immutep Limited and certain officers, alleging they made false and misleading statements about the company's TACTI-004 clinical trial. The lawsuit claims Immutep misrepresented trial progress and risks, leading to investor losses between March 24, 2025, and March 12, 2026. Investors who suffered losses can join the case and have until July 6, 2026, to seek lead plaintiff status. The law firm works on a contingency fee basis, meaning investors pay only if the case succeeds.